Sleep Apnea Market Expected to Experience Accelerated Growth and Market Evolution by 2034 - DelveInsight | Apnimed, Eli Lilly, Incannex Healthcare, Axsome Therapeutics, Jazz Pharma, Bioprojet

The Key Sleep Apnea Companies in the market include - Apnimed, Eli Lilly and Company, Incannex Healthcare, Axsome Therapeutics/Jazz Pharmaceuticals, Bioprojet, and others.

The Sleep Apnea market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Sleep Apnea pipeline products will significantly revolutionize the Sleep Apnea market dynamics.

DelveInsight's "Sleep Apnea Market Insights, Epidemiology, and Market Forecast-2034 report offers an in-depth understanding of the Sleep Apnea, historical and forecasted epidemiology as well as the Sleep Apnea market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Sleep Apnea market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Sleep Apnea Market Forecast [https://www.delveinsight.com/sample-request/sleep-apnea-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Some of the key facts of the Sleep Apnea Market Report:

*
The Sleep Apnea market size was valued approximately USD 661 million in 2025 and is anticipated to reach USD 5,681 million by 2034 with a CAGR of 27% during the study period (2020-2034).

*
In June 2026, Eli Lilly reported encouraging results from late-stage clinical trials evaluating retatrutide in adults with obesity and obstructive sleep apnea (OSA). The investigational triple GIP/GLP-1/glucagon receptor agonist demonstrated significant reductions in OSA severity while producing substantial weight loss, highlighting the potential of metabolic therapies as an effective treatment approach for sleep apnea.

*
In May 2026, Apnimed announced positive topline results from its Phase III SynAIRgy trial evaluating AD109, an investigational once-nightly oral therapy for obstructive sleep apnea (OSA). The trial showed significant reductions in the apnea-hypopnea index (AHI) and meaningful improvements in disease severity, supporting the company's plans to pursue regulatory submissions.

*
In March 2026, LivaNova's aura6000 Trademark hypoglossal nerve stimulation system received FDA Premarket Approval (PMA) for the treatment of adults with moderate-to-severe obstructive sleep apnea (OSA) who are unable to tolerate or have not responded adequately to positive airway pressure (PAP) therapy. The implantable neurostimulation device provides an alternative therapeutic option for eligible patients with OSA.

*
In July 2025, Apnimed reported positive topline findings from LunAIRo, its second Phase 3 trial of AD109 (aroxybutynin 2.5 mg, atomoxetine 75 mg) in adults with obstructive sleep apnea. Earlier, in May, the company shared results from its SynAIRgy trial of AD109.T

*
In May 2025, Apnimed reported positive Phase III SynAIRgy trial results for AD109, an oral OSA therapy. The study achieved its primary endpoint, demonstrating a significant reduction in the apnea-hypopnea index (AHI) at 26 weeks compared to placebo. Effectiveness was observed across all severities of OSA and various weight groups. AD109 was well-tolerated, with no serious treatment-related adverse events. These findings support AD109's potential as a first-in-class oral treatment for OSA.

*
In Jan 2025, Mineralys Therapeutics, Inc. announced that the FDA has approved its IND application for a Phase 2 clinical trial to assess lorundrostat for the treatment of Sleep Apnea (OSA) and hypertension. The trial is set to begin in the first quarter of 2025.

*
In December 2024, Eli Lilly and Company (NYSE: LLY) announced that the U.S. Food and Drug Administration (FDA) has approved Zepbound Registered (tirzepatide) as the first and only prescription treatment for adults with moderate-to-severe Sleep Apnea (OSA) and obesity. Zepbound is intended to help alleviate sleep disorders in adults affected by both OSA and obesity.

*
Between 2025 and 2034, pipeline therapies including Eli Lilly's retatrutide and orforglipron, Incannex's IHL-42X, and Apnimed's AD109, among others, are anticipated to fuel growth in the sleep apnea market.

*
The sleep apnea treatment pipeline is advancing quickly, mainly targeting OSA. Key candidates include Eli Lilly's retatrutide and orforglipron, Incannex's IHL-42X, and Apnimed's AD109. Interestingly, SASS-001 from Shionogi Apnimed Sleep Science stands out as the only candidate currently focused on CSA.

*
In 2024, the sleep apnea market across the EU4 and the UK was valued at around USD 120 million, representing nearly 20% of the total 7MM market.

*
In 2024, Japan's sleep apnea market was valued at around USD 20 million.

*
In 2024, the total number of diagnosed prevalent sleep apnea cases in the 7MM was estimated at around 29 million.

*
In 2024, sleep apnea cases in the 7MM were about 15.8 million for mild and 13 million for moderate to severe severity.

*
In 2024, obstructive sleep apnea (OSA) represented nearly 92% of all prevalent sleep apnea cases.

*
In 2024, about 92% of total sleep apnea cases were attributed to obstructive sleep apnea (OSA).

*
Key Sleep Apnea Companies: Apnimed, Eli Lilly and Company, Incannex Healthcare, Axsome Therapeutics/Jazz Pharmaceuticals, Bioprojet, and others

*
Key Sleep Apnea Therapies: AD109 (Aroxybutynin + Atomoxetine), Retatrutide, Orforglipron, IHL-42X (Acetazolamide + dronabinol), ZEPBOUND/ MOUNJARO (tirzepatide), SUNOSI (solriamfetol), OZAWADE (Pitolisant), and others

*
The Sleep Apnea epidemiology based on gender analyzed that in 2022, 61% cases of OSA were of males, while 39% cases were of Females in the 7MM

*
The Sleep Apnea market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Sleep Apnea pipeline products will significantly revolutionize the Sleep Apnea market dynamics.

Sleep Apnea Overview

Sleep apnea is a sleep disorder in which breathing repeatedly stops and starts during sleep. It leads to poor sleep quality, loud snoring, and daytime fatigue. The most common types are obstructive sleep apnea (OSA), caused by airway blockage, and central sleep apnea (CSA), caused by the brain not sending proper signals to control breathing. If untreated, it can increase the risk of high blood pressure, heart disease, stroke, and diabetes.

Get a Free sample for the Sleep Apnea Market Forecast, Size & Share Analysis Report:

https://www.delveinsight.com/report-store/sleep-apnea-market [https://www.delveinsight.com/report-store/sleep-apnea-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Sleep Apnea Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Sleep Apnea Epidemiology Segmentation:

The Sleep Apnea market report proffers epidemiological analysis for the study period 2020-2034 in the 7MM segmented into:

*
Total Prevalence of Sleep Apnea

*
Prevalent Cases of Sleep Apnea by severity

*
Gender-specific Prevalence of Sleep Apnea

*
Diagnosed Cases of Episodic and Chronic Sleep Apnea

Download the report to understand which factors are driving Sleep Apnea epidemiology trends @ Sleep Apnea Epidemiology Forecast [https://www.delveinsight.com/sample-request/sleep-apnea-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Sleep Apnea Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Sleep Apnea market or expected to get launched during the study period. The analysis covers Sleep Apnea market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Sleep Apnea Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Sleep Apnea Therapies and Key Companies

*
AD109 (Aroxybutynin + Atomoxetine): Apnimed

*
Retatrutide: Eli Lilly and Company

*
Orforglipron: Eli Lilly and Company

*
IHL-42X (Acetazolamide + dronabinol): Incannex Healthcare

*
ZEPBOUND/ MOUNJARO (tirzepatide): Eli Lilly and Company

*
SUNOSI (solriamfetol): Axsome Therapeutics/Jazz Pharmaceuticals

*
OZAWADE (Pitolisant): Bioprojet

Discover more about therapies set to grab major Sleep Apnea market share @ Sleep Apnea Treatment Landscape [https://www.delveinsight.com/sample-request/sleep-apnea-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Sleep Apnea Market Drivers

*
Rising prevalence of obstructive sleep apnea (OSA) driven by increasing obesity rates, aging populations, and sedentary lifestyles is expanding the patient pool.

*
Growing awareness of sleep disorders and their association with cardiovascular disease, diabetes, stroke, and hypertension is encouraging early diagnosis and treatment.

*
Advancements in diagnostic technologies, including home sleep apnea testing (HSAT), wearable monitoring devices, and AI-powered sleep analysis, are improving detection rates.

*
Increasing adoption of CPAP, BiPAP, oral appliances, and hypoglossal nerve stimulation devices is supporting market growth.

*
Expansion of innovative pharmacological therapies targeting sleep apnea is creating new opportunities beyond device-based treatments.

Sleep Apnea Market Barriers

*
High rate of underdiagnosis, particularly among patients with mild or asymptomatic disease, continues to limit treatment uptake.

*
Poor long-term adherence to CPAP therapy due to discomfort, inconvenience, and patient intolerance remains a significant challenge.

*
High costs of advanced sleep apnea devices and surgical interventions may restrict access, particularly in low- and middle-income countries.

*
Limited availability of approved pharmacological treatments reduces therapeutic options for patients unable to tolerate device-based therapies.

*
Variability in reimbursement policies across healthcare systems can hinder patient access to innovative treatments.

Scope of the Sleep Apnea Market Report

*
Study Period: 2020-2034

*
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

*
Key Sleep Apnea Companies: Apnimed, Eli Lilly and Company, Incannex Healthcare, Axsome Therapeutics/Jazz Pharmaceuticals, Bioprojet, and others

*
Key Sleep Apnea Therapies: AD109 (Aroxybutynin + Atomoxetine), Retatrutide, Orforglipron, IHL-42X (Acetazolamide + dronabinol), ZEPBOUND/ MOUNJARO (tirzepatide), SUNOSI (solriamfetol), OZAWADE (Pitolisant), and others

*
Sleep Apnea Therapeutic Assessment: Sleep Apnea current marketed and Sleep Apnea emerging therapies

*
Sleep Apnea Market Dynamics: Sleep Apnea market drivers and Sleep Apnea market barriers

*
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies

*
Sleep Apnea Unmet Needs, KOL's views, Analyst's views, Sleep Apnea Market Access and Reimbursement

To know more about Sleep Apnea companies working in the treatment market, visit @ Sleep Apnea Clinical Trials and Therapeutic Assessment [https://www.delveinsight.com/sample-request/sleep-apnea-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Table of Contents

1. Sleep Apnea Market Report Introduction

2. Executive Summary for Sleep Apnea

3. SWOT analysis of Sleep Apnea

4. Sleep Apnea Patient Share (%) Overview at a Glance

5. Sleep Apnea Market Overview at a Glance

6. Sleep Apnea Disease Background and Overview

7. Sleep Apnea Epidemiology and Patient Population

8. Country-Specific Patient Population of Sleep Apnea

9. Sleep Apnea Current Treatment and Medical Practices

10. Sleep Apnea Unmet Needs

11. Sleep Apnea Emerging Therapies

12. Sleep Apnea Market Outlook

13. Country-Wise Sleep Apnea Market Analysis (2020-2034)

14. Sleep Apnea Market Access and Reimbursement of Therapies

15. Sleep Apnea Market Drivers

16. Sleep Apnea Market Barriers

17. Sleep Apnea Appendix

18. Sleep Apnea Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=sleep-apnea-market-expected-to-experience-accelerated-growth-and-market-evolution-by-2034-delveinsight-apnimed-eli-lilly-incannex-healthcare-axsome-therapeutics-jazz-pharma-bioprojet]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.